Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas

Sarcomas are rare tumors derived from mesenchymal connective tissues in the body. Because there are well over 50 histologic sarcoma subtypes, including malignant and non-malignant pathologies, clinical courses and therapeutic management are widely divergent. In general, therapeutic options across al...

Descripción completa

Detalles Bibliográficos
Autores principales: Choe, Jennifer, Riedel, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221061/
https://www.ncbi.nlm.nih.gov/pubmed/30450193
http://dx.doi.org/10.12688/f1000research.15868.1
_version_ 1783368948818903040
author Choe, Jennifer
Riedel, Richard
author_facet Choe, Jennifer
Riedel, Richard
author_sort Choe, Jennifer
collection PubMed
description Sarcomas are rare tumors derived from mesenchymal connective tissues in the body. Because there are well over 50 histologic sarcoma subtypes, including malignant and non-malignant pathologies, clinical courses and therapeutic management are widely divergent. In general, therapeutic options across all soft tissue sarcomas are limited in number and are often generalized across multiple sarcoma histologies. The recent emergence of molecularly targeted therapies and immune-based agents presents a future of refined systemic treatment practices that are rationally tailored to the tumor by histologic subtype and biologic mechanisms.
format Online
Article
Text
id pubmed-6221061
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-62210612018-11-15 Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas Choe, Jennifer Riedel, Richard F1000Res Review Sarcomas are rare tumors derived from mesenchymal connective tissues in the body. Because there are well over 50 histologic sarcoma subtypes, including malignant and non-malignant pathologies, clinical courses and therapeutic management are widely divergent. In general, therapeutic options across all soft tissue sarcomas are limited in number and are often generalized across multiple sarcoma histologies. The recent emergence of molecularly targeted therapies and immune-based agents presents a future of refined systemic treatment practices that are rationally tailored to the tumor by histologic subtype and biologic mechanisms. F1000 Research Limited 2018-11-02 /pmc/articles/PMC6221061/ /pubmed/30450193 http://dx.doi.org/10.12688/f1000research.15868.1 Text en Copyright: © 2018 Choe J and Riedel R http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Choe, Jennifer
Riedel, Richard
Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas
title Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas
title_full Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas
title_fullStr Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas
title_full_unstemmed Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas
title_short Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas
title_sort making progress in a rare disease: emerging therapeutics in soft tissue sarcomas
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221061/
https://www.ncbi.nlm.nih.gov/pubmed/30450193
http://dx.doi.org/10.12688/f1000research.15868.1
work_keys_str_mv AT choejennifer makingprogressinararediseaseemergingtherapeuticsinsofttissuesarcomas
AT riedelrichard makingprogressinararediseaseemergingtherapeuticsinsofttissuesarcomas

Ejemplares similares